Nav: Home

Parents ranked cancer prevention as number one provider reason for HPV vaccination

June 14, 2018

CHAPEL HILL - Parents ranked cancer prevention as the most compelling reason health care providers can give for recommending the human papillomavirus (HPV) vaccine, according to a survey led by University of North Carolina Lineberger Comprehensive Cancer Center researchers.

The findings, published in the journal Cancer Epidemiology, Biomarkers and Prevention, offer guidance as to what doctors and other health care providers should be emphasizing to parents when discussing vaccination for their children against HPV, a sexually transmitted virus that can cause oral, head and neck, genital and cervical cancers.

"Parents confirmed the advice from the CDC and other professional organizations, which is cancer prevention is the most important reason for HPV vaccination," said UNC Lineberger's Melissa B. Gilkey, PhD, assistant professor in the UNC Gillings School of Global Public Health. "Providers report giving a wide variety of reasons to vaccinate, but this study suggests what parents really want to hear about is cancer prevention. This was true even for parents who had relatively low confidence in adolescent vaccination."

The U.S. Centers for Disease Control and Prevention estimates 41,000 people are diagnosed with HPV-associated cancer in the United States each year. HPV vaccination could prevent most HPV-linked cancers, which include cancers of the throat, the cervix, and genitals. However, just 43 percent of adolescents were up-to-date on the HPV vaccine in the United States in 2016, according to the CDC. Studies have shown that a provider's recommendation is highly influential.

"Research has shown that a provider's recommendation is the single most important factor in whether parents decide to get their kids vaccinated," Gilkey said. "Public health organizations, including the Centers for Disease Control and Prevention, are leading large-scale campaigns to improve provider communication about HPV vaccination. We're working to understand what the most powerful messages are to inform those ongoing interventions."

The researchers drew their findings from a survey of 1,177 adults in the United States with children between the ages 11 and 17. The parents were asked to rank, from best to worst, a list of reasons a doctor commonly use to encourage parents to consider vaccinating their child against HPV.

Parents said cancer prevention was the most persuasive reason for HPV vaccination. The prevention of a common infection, the vaccine's lasting benefits and its safety also scored high. Reasons that received low rankings included "it is a scientific breakthrough," and "I got it for my own child."

When the researchers compared the responses from parents who had low confidence in adolescent vaccines at the outset, they found these parents ranked messages very similarly to parents who had high confidence. "This should give providers confidence that leading with the idea of cancer prevention doesn't have to be targeted toward a particular type of parent," Gilkey said. "Cancer prevention is likely to be your best bet no matter who you're talking to."
-end-
In addition to Gilkey, other authors were Mo Zhou, Annie-Laurie McRee, Melanie L. Kornides and John F.P. Bridges.

The study was supported by the National Cancer Institute.

UNC Lineberger Comprehensive Cancer Center

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".